Expand OGEN Menu
OGEN MENU

OGEN Latest Press Releases

-- April 20, 2026 --

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury Globe Newswire 9:00 AM

-- April 13, 2026 --

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury Globe Newswire 8:30 AM

-- March 25, 2026 --

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation Globe Newswire 6:30 PM

-- March 17, 2026 --

ORAGENICS FILES ANNUAL REPORT ON FORM 10-K Globe Newswire 8:30 AM

-- March 12, 2026 --

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION Globe Newswire 8:30 AM

-- March 11, 2026 --

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION Globe Newswire 8:30 AM

-- March 10, 2026 --

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia Globe Newswire 8:30 AM

-- February 9, 2026 --

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy Globe Newswire 8:30 AM

-- February 3, 2026 --

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program Globe Newswire 8:30 AM

-- February 2, 2026 --

Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care Globe Newswire 8:30 AM

-- January 14, 2026 --

Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes